|
Synonyms: LY-3127804 | LY3127804
Compound class:
Antibody
Comment: Zansecimab (LY3127804) is a humanised IgG4 monoclonal antibody that targets angiopoietin 2 (Ang2). It was designed and developed by Eli Lilly to block angiogenesis as an anti-tumour mechanism. As Ang2 is elevated in acute respiratory distress syndrome (ARDS), Eli Lilly chose to evaluate LY3127804 in patients hospitalised with COVID-19 pneumonia, to ascertain if this approach could reduce the risk of developing ARDS in at risk patients. The COVID study was terminated for futility after around 6 months.
The peptide chain sequences of zansecimab (from its INN submission) are identical to sequences claimed in Eli Lilly's patent WO2015179166A1: sequences 2 and 4 comprise the heavy and light chains of the mAb designated as 'Antibody A' in the patent [1]. |
| No information available. |
Summary of Clinical Use  |
| Being evaluated in solid tumours. A study in COVID-19 patients was terminated as zansecimab was considered unlikely to be effective. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04342897 | A Study of LY3127804 in Participants With COVID-19 | Phase 2 Interventional | Eli Lilly and Company | This trial was terminated in late October 2020 for futility. | |
| NCT02597036 | A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors | Phase 1 Interventional | Eli Lilly and Company | 2 | |
